3 Reasons Aphria (TSX:APHA) Stock Is Looking Better Than Ever

With its larger competitors beginning to stall out, Aphria Inc (TSX:APHA)(NYSE:APHA) is looking better than ever

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Aphria Inc (TSX:APHA)(NYSE:APHA) has long been one of the more controversial marijuana stocks. Between short attacks, shareholder lawsuits, and a hostile takeover bid, the company has been involved in more drama than any of the other major weed producers. As a result of the bad press, Aphria was once among the most hated weed companies.

Now, however, with Canopy Growth Corp (TSX:WEED)(NYSE:CGC) losing money and other producers stalling out, it’s beginning to look like one of the best in its class. The following are just three reasons why Aphria stock is looking better than ever.

The fastest-growing weed producer

The most obvious thing that will stand out in Aphria’s third quarter earnings report is the incredible growth. At 617% year-over-year, it exceeds any other weed producer and puts the company within striking distance of Canopy’s sales figures. While Aphria’s recreational sales fell 35%, that was more than made up for by medical and revenue generated by new acquisitions: CC Pharma and ABP. Now, Aphria is just a smidgen smaller than Aurora–and a whole lot cheaper.

Last year’s drama completely resolved

Aphria’s stock suffered last year due to the highly publicized controversies it had been embroiled in. Now, it looks like it’s smooth sailing ahead. As previously mentioned, Aphria’s latest report revealed that much of its revenue is coming from new acquisitions CC Pharma and ABP–completely undermining the claim that such acquisitions had been worthless.

Additionally, most of the high-profile investors who had been short APHA have closed out their positions, so the “short attack” threat is no longer a factor. Finally, while the class-action lawsuit against Aphria appears to be going ahead, the company’s relative success in recent quarters could result in a favourable outcome for the company.

Larger competitors running into problems

A final factor making Aphria look good right now is the competitive landscape in the cannabis space. Simply put, many of Aphria’s competitors aren’t doing so well, which makes Aphria look good by comparison.

Case in point: Canopy Growth. In its most recent quarter, that company posted a $323 million net loss and a $174 million operating loss. In its full year results, it posted a $670 million loss. This is a company that’s burning through cash at a frightening pace–so much so that the markets aren’t rewarding its revenue growth.

The problems with Canopy recently got so bad that the company’s biggest investor publicly stated they were “not pleased” with their results–and may have instigated the ouster of CEO Bruce Linton.

In an industry in which disappointing results are becoming the norm, Aphria’s red-hot growth stands out. It should be noted that Aphria itself is running net losses, but they’re much smaller as a percentage of revenue than Canopy’s.

Additionally, Aphria has posted positive earnings in several quarters, thanks in no small part to its long-term investment portfolio, which may make Aphria look increasingly appealing as investors get hungry for earnings.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »